Results 191 to 200 of about 27,503 (257)

Associations Between Antidiabetic Pharmacotherapy and Hearing Thresholds in Adult Hearing‐Impaired Patients With Type 2 Diabetes

Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
ABSTRACT Type 2 diabetes mellitus (T2DM) has increasingly been identified as a risk factor for sensorineural hearing loss, whereas the association between different antidiabetic therapies and hearing thresholds remains poorly characterized. This retrospective observational study evaluated 240 patients with T2DM and 105 normoglycemic controls who ...
Francesco Martines, Pietro Salvago, Francesca Vaccaro, Davide Vaccaro, Ginevra Malta, Fabiana Plescia, Stella Cascioferro, Gianluca Lavanco, Fulvio Plescia   +8 more
wiley   +1 more source

Expert Consensus on Dipeptidyl Peptidase-4 Inhibitor-Based Therapies in the Modern Era of Type 2 Diabetes Mellitus Management in India. [PDF]

Cureus
Kalra S, Bhattacharya S, Dhingra A, Das S, Kapoor N, Shaikh S, Kolapkar V, Lokesh Kumar RV, Patel K, Kotwal R.   +9 more
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Agonists and Blood Pressure Regulation: Molecular Mechanisms and Cardiovascular Implications

Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
ABSTRACT Incretin effect helps in regulating glucose homeostasis and maintaining glycaemic control within the human body. This effect is achieved by the two naturally occurring incretin hormones: glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1).
Nora H. J. Alharbi
wiley   +1 more source

Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase 4 Inhibitor. [PDF]

Adv Ther
Evans M, Husain M, Srivastava A, Mangla KK, Kuhlman AB, Lingvay I.   +5 more
europepmc   +1 more source

Correction to "Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial". [PDF]

Diabetes Obes Metab
europepmc   +1 more source

Association between dipeptidyl peptidase-4 inhibitor use and diabetic retinopathy: a systematic review and meta-analysis of real-world studies. [PDF]

BMC Ophthalmol
Wang M, Lu J, Dong J.
europepmc   +1 more source

Effectiveness and Safety of Fixed‐Dose Combination Metformin and Empagliflozin in Type 2 Diabetes: A Prospective, Multicenter, Real‐World Study From China

Journal of Diabetes, Volume 18, Issue 10, October 2026.
This large‐scale real‐world Chinese study demonstrates glycemic clinical control rates (HbA1c > 7%) at baseline and 6 months across key subgroups, including age, baseline HbA1c, body mass index, and treatment regimen. In this prospective real‐world study of fixed‐dose combination metformin and empagliflozin in Chinese patients with type 2 diabetes ...
Weijian Ke, Yinghong Kong, Songbo Fu, Liyun Wang, Ying Pan, Shao Zhong, Yanhua Jiang, Hui Chen, Xuehua Jiao, Fuxing Sha, Liwu Xu, Wei Shao, Fenghua Lan, Xiaoli Chen, Bo Yan, Guangju Zhou, Ping Shi, Fen Li, Huike He, Hong Li, Guangwu Zhang, Hongyu Duan, Fang Wang, Weikun Gong, Yuxiao Bai, Bin Wang, Xin Mou, Liying He, Wukun Ma, Junhua Song, Juan Zheng, Xiaosu Bai, Xiaosi Li, Xin Yan, Yanqiu Wang, Zhenhua Wang, Juan Yuan, Wei Lu, Yuan Liang, Yufan Wang, Fenjuan Xu, Xuefeng Li, Xuan Lin, Hongbin Zhu, Lingling Xu, Xiaojia Lou, Lingxiao Wang, Lijuan Cui, Lijun Wang, Hua Qian, Yuwen Shi, Yanbing Li   +51 more
wiley   +1 more source

Human β‐Cell Dedifferentiation and Diabetes

Journal of Diabetes, Volume 18, Issue 10, October 2026.
Human β‐cell dedifferentiation is inversely associated with HOMA‐β and occurs in Type 2 diabetes, Type 3c diabetes, and age‐related diabetes, potentially before hyperglycemia develops. Progressive loss of β‐cell identity is accompanied by dedifferentiation and transdifferentiation, suggesting that reversing these cell‐state changes may help restore ...
Jiajun Sun, Jinsook Son, Qidi Wang
wiley   +1 more source

Dipeptidyl peptidase 4 inhibitor sitagliptin decreases myocardial fibrosis and modulates myocardial insulin signaling in a swine model of chronic myocardial ischemia. [PDF]

PLoS One
Harris DD, Sabe SA, Broadwin M, Stone C, Bellam K, Malhotra A, Abid MR, Sellke FW.   +7 more
europepmc   +1 more source

Use of Glucagon‐Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009–2024

Acta Psychiatrica Scandinavica, Volume 154, Issue 4, Page 305-312, October 2026.
ABSTRACT Introduction Diabetes, obesity and bipolar disorder often co‐occur and may have shared pathophysiology. Glucagon‐like peptide 1 receptor agonists (GLP‐1RA) treat diabetes and obesity but their impact on bipolar disorder is unknown. In this era of stagnated pharmacotherapy, we examined psychiatric hospitalisation and absence from work due to ...
Heidi Taipale, Mark Taylor, Markku Lähteenvuo, Ellenor Mittendorfer‐Rutz, Antti Tanskanen, Jari Tiihonen   +5 more
wiley   +1 more source